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Significantly reduced levels of the anti-inflammatory gaseous transmitter hydrogen
sulfide (H2S) are observed in diabetic patients and correlate with microvascular
dysfunction. H2S may protect the microvasculature by preventing loss of the
endothelial glycocalyx. We tested the hypothesis that H2S could prevent or treat
retinal microvascular endothelial dysfunction in diabetes. Bovine retinal endothelial
cells (BRECs) were exposed to normal (NG, 5.5 mmol/L) or high glucose (HG,
25 mmol/L) ± the slow-release H2S donor NaGYY4137 in vitro. Glycocalyx
coverage (stained with WGA-FITC) and calcein-labeled monocyte adherence were
measured. In vivo, fundus fluorescein angiography (FFA) was performed in normal
and streptozotocin-induced (STZ) diabetic rats. Animals received intraocular injection
of NaGYY4137 (1 µM) or the mitochondrial-targeted H2S donor AP39 (100 nM)
simultaneously with STZ (prevention) or on day 6 after STZ (treatment), and the ratio
of interstitial to vascular fluorescence was used to estimate apparent permeability.
NaGYY4137 prevented HG-induced loss of BREC glycocalyx, increased monocyte
binding to BRECs (p ≤ 0.001), and increased overall glycocalyx coverage (p ≤ 0.001).
In rats, the STZ-induced increase in apparent retinal vascular permeability (p ≤ 0.01)
was significantly prevented by pre-treatment with NaGYY4137 and AP39 (p < 0.05)
and stabilized by their post-STZ administration. NaGYY4137 also reduced the number
of acellular capillaries (collagen IV + /IB4-) in the diabetic retina in both groups
(p ≤ 0.05). We conclude that NaGYY4137 and AP39 protected the retinal glycocalyx
and endothelial permeability barrier from diabetes-associated loss of integrity and
reduced the progression of diabetic retinopathy (DR). Hydrogen sulfide donors that
target the glycocalyx may therefore be a therapeutic candidate for DR.
Keywords: glycocalyx, retinal permeability, diabetes, hydrogen sulfide, inflammation, mitochondria, slow-release
hydrogen sulfide donors
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INTRODUCTION
Loss of integrity of the vascular permeability barrier is associated
with a range of pathological conditions. In particular, increased
permeability is observed in diabetes, and in hyperglycemic
conditions (Gillies et al., 1997; Brownlee, 2001; Allen and
Bayraktutan, 2009; Saker et al., 2014) where it is associated
with the pathogenesis of life-altering diabetic microvascular
complications such as retinopathy (Sander et al., 2007). The
vascular permeability barrier is formed of endothelial cells
(ECs), their underlying basement membrane, and the endothelial
glycocalyx. The latter is now recognized as a key regulator of
permeability as demonstrated by a range of studies showing that
selective loss of specific glycocalyx components is associated with
altered permeability properties in various vascular beds (Jeansson
and Haraldsson, 2003; Singh et al., 2007; Landsverk et al., 2012;
Betteridge et al., 2017; Onions et al., 2019).
A role for endothelial glycocalyx damage in diabetes-
associated vascular changes has been described. Glycocalyx
reduction is associated with increased vascular permeability and
increased leucocyte and platelet adhesion in acute hyperglycemia
and diabetes (Nieuwdorp et al., 2006a,b; Broekhuizen et al.,
2010; Kumase et al., 2010), which were reversed by glycocalyx
restoration experimentally in animals (Henry and Duling, 1999;
Constantinescu et al., 2003). Strategies to reverse or reduce
glycocalyx damage in diabetes have the potential to rescue some
of the potentially damaging vascular changes that underlie the
development of vascular complications such as retinopathy.
We hypothesized that exogenous application of hydrogen
sulfide (H2S) may protect the glycocalyx in diabetes, reversing
or preventing the retinal vascular leakage observed in diabetic
retinopathy (DR). Hydrogen sulfide has recently been identified
as a seemingly ubiquitous “gaseous mediator” in mammals
and humans where it is synthesized by multiple cell types
by at least four distinct enzyme systems utilizing endogenous
sulfur-containing amino acids. These systems include the
cytosolic cystathionase (CSE), cystathionine-β-synthase (CBS),
mitochondrial cysteine aminotransferase/3-mercaptopyruvate
sulfurtransferase (CAT/3MST), and D-amino acid oxidase/3-
mercaptopyruvate sulfurtransferase (DAO/3MST) (Whiteman
et al., 2011; Szabo, 2012; Wang, 2012; Szabo et al., 2014). The first
three, at least have been demonstrated in ECs (Wang, 2012; Tao
et al., 2013; Mitidieri et al., 2020). Experimentally, manipulation
of H2S level has been achieved by pharmacological inhibition
or genetic removal of enzyme systems for H2S and the use of
H2S delivery molecules, albeit generally limited to the use of
simple inorganic sulfide salts [e.g., sodium hydrosulfide (NaSH)
or disodium sulfide (Na2S)]. These studies have revealed that
H2S and/or physiologically derived species exert a wide variety
of effects on different organ systems including regulation of
vascular tone (Yang et al., 2008; Kanagy et al., 2017; Szabo, 2017),
inflammation (Whiteman and Winyard, 2011), aging and health
span (Ng et al., 2018; Zivanovic et al., 2019), and more recently as
a regulator of retinal physiology (Du et al., 2017).
There is increasing evidence for impaired vascular EC
synthesis and/or bioavailability of H2S in diabetes (Szabo, 2012).
Lower vascular and/or tissue levels of “H2S” have been observed
in humans with diabetes (Whiteman et al., 2010a; Suzuki
et al., 2017), and in several animal diabetic models, including
streptozotocin (STZ)-treated rats (Yusuf et al., 2005; Si et al.,
2013; Zhou et al., 2014) and mice (Suzuki et al., 2011) and
in db/db (Peake et al., 2013; Sun et al., 2018), ob/ob (Zhao
et al., 2017), Akita (Kundu et al., 2013; John et al., 2017),
and NOD (Brancaleone et al., 2008) mice. Administration of
often high doses of H2S via sulfide salts at least partially
prevented the diabetic phenotype in some of these studies.
In the STZ diabetes model specifically, retinal levels of H2S
were lower in diabetic animals compared with controls (Si
et al., 2013), and retinal capillary leakage, VEGF levels, and
oxidative stress markers were partially normalized after NaSH
treatment (Si et al., 2013). NaSH administration also partially
restored mitochondrial function, e.g., increased ATP synthesis
and complex II and III activity and prevented mitochondrial
oxidant production and mitochondrial swelling, demonstrating
a likely mitochondrial target for pharmacological H2S (Si et al.,
2013). Collectively, these studies strongly suggest that diabetes
and diabetic retinopathy (DR) result from “H2S deficiency,”
which could at least be partially overcome by pharmacological
manipulation of mitochondrial H2S levels.
It is important to note that these previous studies on H2S
and diabetes have exclusively relied on the use of sulfide salts
to generate H2S (e.g., NaSH and Na2S). While useful laboratory
tools for H2S generation, they are not without severe limitations
(Whiteman et al., 2011). These include generation of an instant,
and unphysiological bolus of H2S by pH-dependent dissociation
(and rapid decay), whereas endogenous organic enzymatic H2S
synthesis produces low levels of H2S over prolonged periods of
time (Li et al., 2008; Whiteman et al., 2010b, 2011; Kabil and
Banerjee, 2014).
It is now recognized that mitochondrial oxidative stress may
contribute to the pathogenesis of diabetic endothelial dysfunction
(Brownlee, 2005) and that in diabetes, the primary target for
H2S activity appears to be the mitochondria where it is used
as an electron source for respiration to reduce oxidative stress
(Módis et al., 2014; Szabo et al., 2014). This is supported by data
indicating that mitochondrial-targeted slow-release H2S donors
preserved cellular bioenergetics and increased levels of Nrf2 and
peroxisome proliferator-activated receptor-gamma coactivator
(PGC-1α), key regulators of mitochondrial antioxidant capacity,
bioenergetics, and biogenesis, both in vitro and in vivo in
response to UVA-induced photoaging (Lohakul et al., 2021).
However, H2S concentrations (derived from sulfide salts)
that are required to reverse mitochondrial dysfunction in the
vasculature (e.g., in diabetic rats) are unattainable (Suzuki et al.,
2011; Montoya and Pluth, 2016). This is presumably because
H2S from these tools is generated immediately, locally, and not
targeted to mitochondria. With the development of the slow-
release cytosolic donor sodium GYY4137 (Li et al., 2008) and
the mitochondria-specific sulfide donor AP39 (Le Trionnaire
et al., 2014) the limitations of NaSH/Na2S have been overcome.
The effects on microvascular EC and in the kidney have been
previously reported (Ahmad et al., 2016; Gerő et al., 2016), but
to the best of our knowledge, no previous studies have reported
on the effects of these molecules in DR.
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In this current study, we investigated the effects of a single
dose (administered by intravitreal injection) of two slow-release
H2S donor molecules, the cytosolic sodium GYY4137 (Li et al.,
2008) and the mitochondria-specific sulfide donor AP39 (Le
Trionnaire et al., 2014), on retinal vascular permeability in vivo
in the Norway Brown rat streptozotocin-induced DR model. In
addition, the effects of these two H2S generators on in vitro
EC glycocalyx thickness using bovine retinal endothelial cells
(BRECs) were studied. Leucocyte adhesion to BRECs and the




The mitochondria-targeted H2S donor AP39 was synthesized
in our laboratories as previously described by our team (Le
Trionnaire et al., 2014). Commercially available GYY4137
is a morpholine salt that contains unstated quantities of
dichloromethane residual from its initial synthesis and which
forms part of the lattice structure (at least 2 dichloromethane:1
GYY4137 molecule) (Alexander et al., 2015), i.e., it is
commercially available as xCHCl2 or a dichloromethane
complex. Dichloromethane is metabolized in vivo to carbon
monoxide (Ratney et al., 1974; Takano and Miyazaki, 1988).
Furthermore, the morpholinium counter ion (1 morpholine:1
GYY4137 molecule) is not biologically inert and has a half-life in
rats of ∼90 min (Sohn et al., 1982). LD50 values for morpholine
in rats and mice, e.g., 100–400 mg/kg for i.p. administration
(Kielhorn and Rosner, 1996), are well within the commonly used
doses of commercial GYY4137, e.g., 50–300 mg/kg (Lee et al.,
2011; Li et al., 2013). In the eye, morpholine and dichloromethane
have been reported to cause keratoconjunctivitis, focal/diffuse
cataract formation, keratitis, iritis, conjunctival epithelial
edema and detachment, and denudation of corneal epithelium
(Ballantyne et al., 1976; Brandt and Okamoto, 1988; Toxicology–
cosmetic ingredient review, 1989). To avoid these clinical
indications and associated toxicity, a cleaner dichloromethane
and morpholine-free sodium salt synthesized as previously
described was used in this study (Alexander et al., 2015).
Cell Culture and Treatments
Primary cultures of BRECs were isolated from bovine
retinae dissected from eyes of freshly slaughtered cattle, by
homogenization and a series of filtration steps as previously
described (Chibber et al., 2000). Briefly, excess fat and muscle
tissue was removed from the eye globes and the retina were
dissected, placed in 20 ml of minimal essential medium (MEM)
and homogenized using a hand-held sterile glass homogenizer
to dissociate the neural retina. The resulting homogenate was
filtered through 80-µm nylon mesh, the material remaining
on the mesh was collected, and the trapped microvessels were
resuspended in serum free MEM with collagenase-dispase
(2 mg/ml) and digested for 90 min at 37◦C on a rotator shaker.
Following further filtration through a 45-µm polypropylene
net filter, the trapped microvessel fragments were vigorously
pipetted in MEM with 10% (v/v) pooled human serum, 10%
(v/v) tryptose phosphate broth (TPB), L-glutamine 2 mM,
penicillin (100 U/ml), and streptomycin (100 µg/ml) and
plated in fibronectin-coated tissue culture flasks. After 24 h,
the flasks were rinsed once with MEM to remove debris and
unattached cells and refilled with fresh growth medium [MEM
supplemented with 10% (v/v) pooled human serum, 10% (v/v)
tryptose phosphate broth (TPB), L-glutamine 2 mmol/L, and
penicillin (100 U/ml) and streptomycin (100 µg/ml)]. From
passage 1 onward, the BRECs were cultured on gelatin-coated
tissue culture flasks and human serum was replaced with
10% (v/v) horse serum. Pericyte contamination was removed
by differential trypsinization. Cultures were >90% pure as
assessed by morphology and staining for von Willebrand factor.
Preliminary studies confirmed that treatment with 25 mmol/L
D-mannitol as osmotic control had no effect on either the
glycocalyx or leukocyte adhesion compared with the normal
glucose (NG) treatment. U937 cells (human leukemic monocyte
lymphoma cell line) were cultured in RPMI-1640 with 10%
(v/v) fetal bovine serum, 5.6 mmol/L D-glucose, 25 mmol/L
HEPES, and antibiotics. Based on our preliminary results, a
final concentration of 500 µmol/L of NaGYY4137 was used in
the definitive experiment. NaGYY4137 (500 µmol/L) generates
approximately 1 µmol/L or less of H2S during the incubation
period (Szabo, 2017).
Glycocalyx Assessment
A cell-based fluorescent assay, based on that described by Singh
et al. (2007), was performed to quantify changes within the
glycocalyx using fluorescein isothiocyanate-labeled wheat germ
agglutinin (WGA-FITC). Bovine retinal endothelial cells were
exposed to normal (NG, 5.5 mmol/L) or high glucose (HG,
25 mmol/L) ± GYY4137 (500 µmol/L) in MEM with 0.5%
bovine serum albumin (BSA, w/v) for 24 h. Cells were washed
3× with phosphate buffered saline (PBS) and incubated with
WGA-FITC [2 µg/ml in HEPES-buffered phenol red-free MEM
containing 0.5% BSA (w/v)] for 30 min at 37◦C. After washing
with PBS (3×), fluorescence intensities were measured (Ex/Em,
485/520 nm) using a fluorescence microplate reader. Cells were
lysed and the protein content of each well was measured using the
bicinchoninic acid method. Results are presented as fluorescence
unit/µg of protein.
Leukocyte Adhesion Assay
Bovine retinal endothelial cells (BRECs) were cultured to
confluency in commercially available µ-slide VI0.4 perfusion
slides (Ibidi, München, Germany) coated first with 2% (w/v)
bovine gelatin (2 h) and then overnight with bovine fibronectin
(50 µg/ml). Cells were treated with NG or HG as above. Calcein
acetoxymethyl ester labeled (0.5 µmol/L for 30 min) U937 cells
(1 × 106/ml) were then flowed over confluent BREC cultures at
a laminar shear stress of 1 dyne/cm2 generated by a peristaltic
pump. This shear stress was chosen to mimic venular wall
shear stresses that favor leucocyte adhesion in vivo (Jones et al.,
1995; Sundd et al., 2011). After 6 min, slides were washed
with PBS for 1 min to remove non-adherent cells, fixed in 4%
(w/v) paraformaldehyde, and examined using a Nikon Eclipse
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TS100 (Nikon UK Limited, Kingston upon Thames, Surrey,
United Kingdom) fluorescence microscope to assess the number
of adherent U937 cells (10 random fields of view/slide). All
experiments were performed on at least three separate occasions.
Statistical significance was tested using the Student t-test.
Animal Ethics
Experimental animals were treated in accordance with ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research and under a UK Home Office license at the University
of Nottingham Biological Services Unit.
Streptozotocin-Induced Diabetes
A total of 12 male Norway Brown rats (250–300 g, Envigo,
United States) were weighed and given a single intraperitoneal
(i.p.) injection of STZ (50 mg/kg, Sigma–Aldrich, MO,
United States). A total of six control rats were injected with 300 µl
of saline i.p. On days 0 and 4 and prior to sacrifice (day 7), blood
glucose levels were tested using a sample of blood taken from the
tail vein and an Accuchek blood glucose monitor. Rats with blood
glucose levels of 15 mmol/L and above were deemed diabetic.
Streptozotocin-injected rats that did not become hyperglycemic
on day 4 were re-injected with STZ the following morning and
subsequently included if deemed diabetic following evaluation for
diabetes as outlined above.
Intravitreal Injections
Rats were anaesthetized with a single 10 mg/ml i.p. injection of
Domitor (medetomidine hydrochloride, Pfizer, United Kingdom)
and Ketaset (ketamine hydrochloride, Zoetis, NJ, United States).
Pupils were dilated with topical applications of 5% (w/v)
phenylephrine hydrochloride (Bausch and Lomb) and 0.8%
(w/v) tropicamide (Bausch and Lomb), and eyes were coated
with Lubrithal (Dechra) to prevent dehydration. A 1.5-cm
34-gauge hypodermic needle (Hamilton, NV, United States)
attached to a 5-µl syringe (World Precision Instruments,
FL, United States) was inserted through pars plana at 3 mm
from the limbus into the vitreous of the left eye at a 45◦
angle. Rats received 5 µl of sterile PBS, 1 µmol/L NaGYY4137
[sodium 4-methoxyphenyl(morpholino)-phosphinodithioate],
or 100 nmol/L AP39 [(10-oxo-10-(4-(3-thioxo-3H-1,2-dithiol-
5yl)phenoxy)decyl) triphenylphosphonium bromide] on day 0
(prevention arm) or day 6 (treatment arm).
Fundus Fluorescein Angiography
Angiography was performed as described (Allen et al., 2020).
Sodium fluorescein (NaF) dye was prepared by dissolving in
sterile PBS to give a final concentration of 100 mg/ml and
sterile filtered (0.2 µm). Rats were anesthetized as previously
described and fundus images of the retina were captured to check
for any ocular abnormalities. Rats received a single 250 µl i.p.
injection of sodium fluorescein (100 mg/ml), which was allowed
to circulate for ∼60 s before imaging with a Micron IV Retinal
Imaging Microscope (Phoenix Research Labs). The green filter
was selected, and a 3-min video footage of the retina was recorded
at 15 frames per second. This was carried out on days 0 and
7. Development of cataracts with resultant blurring of posterior
segment view meant that some eyes (n = 2) were excluded from
the consecutive fundus fluorescein angiography (FFA).
Retinal Permeability Model
Angiograms were imported into ImageJ software and
fluorescence was measured in the interstitium and a major
retinal vessel every 200 frames up to 2,400 frames. The
ratio of interstitial to vascular fluorescence was adjusted for
background level and plotted against time and the slope used
to determine an estimate of permeability (Figure 1). Figure 1A
shows images taken from rats given NaF and recording
started within 1 min of injection. The large vessels of the
retina are clearly seen, and the retina becomes brighter over
time. To estimate a measure of permeability, the fluorescence
intensity in an area with no large vessels was measured. The
solute flux (number of fluorescence molecules entering the
interstitium per unit time) was calculated from the change in
fluorescence intensity in the window outside the major vessel, as
a proportion of the fluorescence intensity in the blood vessel in
the same frame, to account for any changes in focus, excitation
intensity, or noise, plotted against the time in seconds. The
permeability surface area product was calculated from the
solute flux, the concentration gradient between the intravascular
and extravascular compartments (difference in fluorescence
intensity), and the area of the extravascular sample measurement
according to Fick’s law. In healthy Norway Brown rats, the
permeability was the same 7 days after intraocular injection with
2 µl saline (7.47 ± 1.74 × 10−4 s−1) as it was before injection
(6.57 ± 2.13 × 10−4 s−1). Streptozotocin treatment resulted in
a significant increase in blood glucose (29.73 ± 0.66 mmol/L)
after 1 week (compared with 7.92 ± 0.37 mmol/L), which was
accompanied by a significant increase in solute flux in the
retina (Figure 4), which translated to an increase in estimated
permeability from 8.19 ± 0.95 × 10−4 s−1 before STZ to
13.32± 1.65× 10−4 s−1 after STZ induction (Allen et al., 2020).
Immunofluorescence
After animal termination and ocular dissection (day 14), retinae
were flat-mounted and blocked in 5% (v/v) goat serum, 3%
(v/v) Triton X-100, 1% (w/v) BSA, and stained with isolectin-
B4 (IB4) (Sigma Aldrich, biotin conjugated) 5 µg/ml and
rabbit anti-collagen IV (Abcam) 5 µg/ml overnight at 4◦C.
Streptavidin conjugated Alexafluor 488 2 µg/ml and donkey
anti-rabbit Alexafluor 555 4 µg/ml were used to detect IB4
and collagen IV staining, respectively. Coverslips were mounted
with Fluoroshield with DAPI. Images were obtained using a
Leica TCS SPE confocal microscope, and all settings were
maintained between images.
Statistics
All statistics and graphs were produced in GraphPad Prism 6 and
statistical tests are shown in figure legends. Significant differences
are indicated on graphs as asterisks, where: ∗p≤ 0.05; ∗∗p≤ 0.01;
∗∗∗p ≤ 0.001.
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FIGURE 1 | Retinal permeability analysis model. (A) Fundus fluorescein angiography was performed in non- and diabetic Norway Brown rats treated ± H2S donors,
on days 0 and 7. The angiograms shown are representative of a non-diabetic animal. (B) The mean intensity of NaF in the retinal tissue (Adamis and Berman, 2008)
and a main retinal vessel (Ahmad et al., 2016) were measured every 200 frames for 3 min. (C) Apparent permeability (Permeability.Surface Area product, PA) was
calculated from the rate of change of extravascular fluorescence (= 1If/1t) per unit concentration difference (1C) between blood and tissue. P = 1If/1t/(1C x A).
1If/1t ∼ slope. 1C = difference between intra- and extravascular intensity.
RESULTS
Glycocalyx Integrity
Two hydrogen sulfide generating molecules were investigated,
NaGYY4137 and AP39. The former is a slow-releasing hydrogen
sulfide donor (Alexander et al., 2015) that does not target any
specific part of the cell, whereas AP39 is a mitochondrial targeted
donor (Le Trionnaire et al., 2014).
HG significantly reduced BREC glycocalyx in vitro (assessed
by FITC-WGA staining) to 89.67% ± 6.6% compared with NG
control conditions (100%), p ≤ 0.001, n = 12–30 (Figure 2).
Simultaneous treatment with the slow-release H2S donor
NaGYY4137 completely reversed this loss and actually restored
the glycocalyx to higher levels than observed in the NG control
(107.49 ± 8.13% vs. 100%, p ≤ 0.001, n = 12–30). Interestingly,
cells incubated in NG conditions in the presence of NaGYY4137
also had significantly higher glycocalyx staining than control
NG-treated cells (106.7± 6.35 vs. 100%, p ≤ 0.001, n = 12–30).
Since the integrity of the glycocalyx may alter endothelial
cell adhesion molecule exposure and thus influence
leukocyte/endothelial binding, adhesion of U937 leukocytes to
a BREC monolayer was examined under the same experimental
conditions. HG significantly increased leukocyte adhesion to
348 ± 110% vs. NG control (100%), p ≤ 0.01, n = 4 (Figure 3).
This increase was fully attenuated to control levels by incubation
with NaGYY4137 (HG + NaGYY4137; 124 ± 47% vs. HG;
348 ± 110%, p ≤ 0.01, n = 4). NaGYY4137 had no significant
effect on leukocyte binding in NG conditions.
Retinal Permeability
To determine the effect of hydrogen sulfide donors on retinal
permeability, fluorescein fundus angiography was carried out
before and after induction of diabetes with STZ. NaF was injected
intraperitoneally into Norway Brown rats and the fluorescence
intensity inside a large vessel and in the tissue outside a large
vessel was determined over time by video-microscopy.
Retinal vascular permeability was significantly increased in the
diabetic Norway Brown rats (23.51 ± 4.59 × 10−4 s−1, n = 3)
compared with normal control rats (9.38 ± 1.40 × 10−4 s−1,
n = 6, Figure 4) on day 28 (p ≤ 0.001) on day 28 and all
other time points. In the H2S donor treatment study no changes
FIGURE 2 | Administration of the slow-release H2S donor NaGYY4137
completely reversed the loss of retinal EC glycocalyx integrity induced by
hyperglycemia. Retinal ECs were incubated with normal (5.5 mmol/L, NG) or
high glucose (25 mmol/L, HG) ± GYY4137 (500 µmol/L) for 24 h before
assessment of glycocalyx integrity with fluorescently labeled lectin
(WGA-FITC). Data are mean ± SD, presented as fluorescence intensity/µg
protein. *p ≤ 0.01 vs. control, **p ≤ 0.01 vs. HG, n = 12–30. One-way
ANOVA.
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FIGURE 3 | Administration of the slow-release H2S donor NaGYY4137 completely attenuated the increased leukocyte adhesion to retinal ECs induced by
hyperglycemia. Retinal ECs were incubated with normal (5.5 mmol/L, NG) or high glucose (25 mmol/L, HG) ± NaGYY4137 (500 µmol/L) for 24 h before examination
of leukocyte adhesion under flow (1 dyne/cm2). (A) Number of adherent U937 cells. Data are mean ± SD. *p ≤ 0.001 vs. control, **p ≤ 0.001 vs. HG, n = 4.
One-way ANOVA. (B) Representative bright field, phase contrast (upper panel) and corresponding fluorescence images (lower panel) of adherent U937 cells stained
with calcein acetoxymethyl ester adhering to a BREC monolayer. Scale bar, 75 µm; original magnification, ×100.
in retinal permeability were measured on day 7 compared to
baseline in non-diabetic animals treated with vehicle control
(saline) (Figure 5A). However, a significant (p ≤0.05) increase in
retinal permeability was measured in non-insulin treated diabetic
animals on day 7 (12.16 ± 0.98 × 10−4 s−1) compared to
baseline (9.23 ± 1.54 × 10−4 s−1) (Figures 5B,C). The slow-
release hydrogen sulfide donor NaGYY4137 significantly reduced
retinal vascular permeability in control, non-diabetic rats after
7 days (3.24 ± 0.66 × 10−4 s−1, p ≤ 0.05, n = 6) vs. day
0 (10.12 ± 1.85 × 10−4 s−1) when administered as a single
preventative intraocular dose pre-diabetes (Figure 5D). Similarly,
NaGYY4137 given in diabetic rats significantly reduced retinal
permeability on day 7 (6.62 ± 1.16 × 10−4 s−1, p ≤ 0.05, n = 6)
vs. day 0 (13.08± 2.61× 10−4 s−1) when given as a preventative
treatment (Figure 5D). When NaGYY4137 was administered
therapeutically, retinal permeability was reduced in control, non-
diabetic animals on day 7 (5.31 ± 1.24 × 10−4 s−1, n = 6) vs.
day 0 (8.90 ± 1.19 × 10−4 s−1, n = 6). More importantly, in
animals with pre-existing diabetes, retinal permeability stabilized
on day 7 (10.27 ± 1.21 × 10−4 s−1, n = 6) compared to day
0 (8.65 ± 1.23 × 10−4 s−1, n = 6) (Figure 5E). Administering
NaGYY4137 treatment prior to the onset of diabetes gave a
68% benefit in reducing retinal permeability compared with
administration to animals with pre-existing diabetes (Figure 5F).
Similarly, the mitochondrial-targeted hydrogen sulfide donor
AP39 significantly reduced retinal permeability in control, non-
diabetic (6.14 ± 0.90 × 10−4 s−1, p ≤ 0.05, n = 6) and diabetic
rats (9.84 ± 1.48 × 10−4 s−1, p ≤ 0.05, n = 6) compared with
day 0 (10.01 ± 1.34 × 10−4 s−1 and 15.52 ± 2.75 × 10−4 s−1,
respectively) when administered as a single preventative dose
(Figure 5G). In addition, AP39 reduced retinal permeability
after a week (5.93 ± 2.25 × 10−4 s−1, n = 6) compared with
baseline (9.49 ± 1.28 × 10−4 s−1, p ≤ 0.05, n = 6) in control
animals when administered therapeutically. However, in diabetic
animals, AP39, when administered therapeutically, stabilized
retinal permeability (13.63 ± 2.56 × 10−4 s−1, n = 5) on day 7
versus baseline (8.99 ± 1.31 × 10−4 s−1, n = 5) (Figure 5H).
Similar to NaGYY4137, administering AP39 treatment prior to
the onset of diabetes gave an 18% benefit in reducing retinal
permeability when compared with animals with pre-existing
diabetes (Figure 5I). Overall, both H2S donors were more
effective in reducing retinal permeability when given to animals
prior to the onset of diabetes. In addition, NaGYY4137 showed
greater efficacy than a 10-fold lower dose of the mitochondrial
targeted AP39 compound.
Acellular Capillary Formation
One of the contributing factors to the pathogenesis of DR is the
presence of acellular capillaries within the retina. These vessels
maintain a basement membrane but have lost the supporting
pericytes and EC cells and thus have no blood flow, promoting
retinal ischemia. In order to assess the effects of NaGYY4137
on acellular capillary formation, retinae were collected at the
end of the retinal permeability study and stained for isolectin
B4, an EC marker, and collagen IV, a major constituent of
the basement membrane. NaGYY4137 was found to reduce the
number of acellular capillaries (collagen IV + /IB4-) in the
diabetic retinae in both the prevention and treatment group to
80.2± 13.9 mm−2 and 66.1± 7.1 mm−2, respectively, compared
with 113.6 ± 11.7 mm−2 in the diabetic retinae (p ≤ 0.05, n = 3,
Figure 6). Despite the increased effectiveness of NaGYY4137
in reducing retinal permeability when administered prior to
diabetes onset, the time of administration appeared to have no
difference in acellular capillary formation.
DISCUSSION
The data presented here indicate, for the first time, that (a)
high glucose-driven glycocalyx loss, (b) high glucose-enhanced
leukocyte adhesion to the endothelium, and (c) diabetes-
associated increases in retinal permeability can all be reversed by
administration of a slow-release H2S donor.
Hyperglycemia-related low-grade persistent inflammation is
thought to contribute to the pathology of early DR (Adamis
and Berman, 2008). Patients with DR have elevated ocular
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FIGURE 4 | Chemically induced diabetes significantly increased retinal vascular permeability in Norway Brown rats compared to non-diabetic controls. (A) Fundus
fluorescein angiography measurements from a single rat carried out on day 0 (before STZ) and day 7 (1 week of STZ treatment). (B) Permeability was measured from
control (blood glucose 7.99 ± 0.21 mmol/L), and (C) diabetic (blood glucose 29.75 ± 1.63 mmol/L) Norway Brown rats on days 0, 7, 14, 21, and 28. Apparent
permeability was calculated as described in the methodology text and depicted in Figure 1. Data including mean ± SEM. *p ≤ 0.001 vs. day 0, **p ≤ 0.0001 vs.
diabetic day 0. One-way ANOVA.
FIGURE 5 | Ocular administration of the slow-release H2S donors reduced retinal permeability in chemically induced diabetic rats. Type I diabetes was successfully
induced in rats following a single dose of STZ and animals were maintained for 1 week without insulin supplementation. Retinal vascular leak was measured on day 0
and day 7 in non- and diabetic animals following treatment. No observed increases in retinal permeability were measured on day 7 in non-diabetic animals treated
with saline (A,C). In diabetic animals treated with saline a significant (*p ≤ 0.05) increase in retinal permeability was measured on day 7 vs. day 0 (B,C). NaGYY4137
and AP39 significantly (*p < 0.05, paired t-test) reduced retinal permeability in non- and diabetic rats (D,G,F) on day 7 when given as a single intraocular
preventative dose, on day 0. In addition, NaGYY4137 and AP39 reduced retinal permeability in non-diabetic rats (E,F,H,I) when administered therapeutically (day 6).
In diabetic rats, NaGYY4137 and AP39 stabilized retinal permeability on day 7 in rats with pre-existing diabetes (E,F,H,I).
levels of inflammatory mediators and the diabetic retina displays
characteristic features of inflammation including increased
vascular permeability and leukocyte adhesion (Adamis and
Berman, 2008). Since a healthy glycocalyx is critical to
maintenance of both the anti-inflammatory and permeability
characteristics of a healthy endothelium, our data highlight
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FIGURE 6 | NaGYY4137 protected against diabetes-induced increase in acellular capillaries. Norway Brown rats were given a single dose of streptozotocin
(50 mg/kg) to induce Type I diabetes. Rats were treated with an intraocular injection of either saline or 1 µmol/L H2S donor NaGYY4137 at day 0 (prevention) or day
6 (treatment). (A) Rats were enucleated at day 7 and whole retinae were mounted and stained with Hoescht, IB4, and collagen IV. The tissue was imaged using
20 × lens. The number of capillaries positively stained for collagen IV but lacking IB4 (white arrows) were counted in three areas of the retina. (B) Acellular capillaries
are expressed per mm2. Error bars represent standard errors of the mean. Statistical analysis was performed using a one-way analysis of variance corrected for false
discovery rate. *p ≤ 0.05.
the potential of H2S donors as new therapeutic tools for the
treatment of DR. Further investigations into optimal dosing and
comparing other H2S delivery molecules are needed to further
explore this potential.
The available literature describing other research in this area
is scarce. However, glycocalyx loss and enhanced leukocyte
adhesion have been reported in a rat model of diabetes
(Kumase et al., 2010). Additionally, a clear link between
in vivo retinal glycocalyx integrity and vascular permeability
has been reported by Leskova et al. (2019), who demonstrated,
in mice, that enzymatic degradation of the glycocalyx is
associated with enhanced retinal permeability. These data
support the hypothesis that maintaining glycocalyx integrity
could be a viable therapeutic strategy for DR. EC glycocalyx
thickness depends on the rate of shedding and circulatory
levels of glycosaminoglycans (GAG)-degrading enzyme levels
(Ikegami-Kawai et al., 2003; Maxhimer et al., 2005). The
previously reported association of glycocalyx reduction with
increased vascular permeability and leucocyte and platelet
adhesion and subsequent reversal by glycocalyx restoration in
experimental animals through increased GAG synthesis (Henry
and Duling, 1999; Constantinescu et al., 2003) corroborate
our findings. Furthermore, Ciszewicz et al. (2009), have
shown that sulodexide attenuates hyperglycemia-associated EC
permeability and inflammation. Similarly, Broekhuizen et al.
(2010), demonstrated that sulodexide increased vascular EC
glycocalyx and reversed the increased vascular permeability
in type 2 diabetes. Additionally, Niu et al. (2019), using
the STZ-induced diabetic rat model used here, showed that
endomucin overexpression restored the diabetes-associated loss
of retinal endothelial glycocalyx and that this restoration was
associated with decreased leukocyte–endothelial adhesion and a
reduction in vessel leakage in rats with DR.
The effects of H2S on the glycocalyx are still unknown.
Although early studies showed potential antioxidant effects of
H2S, more recent work has shown that the reaction rate between
H2S and oxidant species, e.g., peroxide and peroxynitrite,
may be too slow for oxidant scavenging activity alone to
be primarily responsible for glycocalyx- and vaso-protection,
especially given the low in vivo concentrations of H2S, which
we have modeled using NaGYY4317 (Carballal et al., 2011).
This strongly suggests that H2S is acting via other mechanisms
to maintain the glycocalyx during hyperglycemic damage, e.g.,
enhancing synthesis of glycocalyx components or preventing
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hyperglycemia-induced glycocalyx degradation. For instance,
the glycocalyx component syndecan-1 is cleaved by matrix
metalloproteinase-9 (MMP-9) and both activity and expression
of the protease are known to be reduced by H2S administration
(Du et al., 2017). It has also been reported that MMP-7 can
cleave chondroitin sulfate (Lipowsky, 2011) and syndecans 1
and 4 (Manon-Jensen et al., 2013) and our unpublished data
indicate that NaGYY4137 inhibits MMP-7 in in vitro assays at
concentrations similar to those used in the studies described
here. Interestingly, our additional preliminary data indicating
that NaGYY4137 reduces shedding of hyaluronic acid from
cultured ECs suggest another potential action of H2S since
the significant reduction in EC glycocalyx observed in acute
hyperglycemia (Nieuwdorp et al., 2006b) and in types 1 and type
2 diabetes (Nieuwdorp et al., 2006a; Broekhuizen et al., 2010)
is thought to be related to increased hyaluronidase catabolism
(Nieuwdorp et al., 2006a).
It is interesting to note that NaGYY4137 treatment in NG
enhanced glycocalyx staining above the levels observed in NG
alone (Figure 2), suggesting that H2S supplementation alone
increased glycocalyx density. As mentioned previously, the
glycocalyx is a dynamic structure and thus this observation
could potentially be explained by the ability of H2S to
modify glycocalyx-degrading enzymes to reduce their activity.
Interestingly, H2S is the only molecule known to induce protein
S-persulfidation (S-sulfhydration), a recently identified and
unique post-translational protein modification. It is possible that
the activity of glycocalyx-degrading enzymes such as heparinase
might be altered by persulfidation of the cysteine residues of its
active site. Additionally, cysteine residues in proteins have the
potential to be redox modified by H2S in a non-S-persulfidation
manner and several potential glycocalyx-degrading enzymes,
including the proteinases MMP-1 (Lohakul et al., 2021), MMP-2,
MMP-7, and MMP-9, have a cysteine in their active site. Thus, as
has been shown with other zinc proteases including angiotensin-
converting enzyme (Laggner et al., 2007) and TNF-α-converting
enzyme (Li et al., 2013), H2S has the potential to modulate
the glycocalyx-degrading enzyme activity of the proteinases,
although further work is needed to confirm this hypothesis.
The effectiveness of our mitochondrial targeted H2S donor
in decreasing retinal leakage in vivo raises the possibility
of mitochondrial involvement in the observed effects. Modis
et al. reported that endogenous mitochondrial H2S production
was governed by MST (Módis et al., 2013). Additionally, Si
et al. (2013) reported that DR was associated with significant
decreases in retinal H2S levels and expression of the H2S
synthesizing enzymes CSE, CBS, and 3MST (i.e., DR resulted in
retinal H2S deficiency) and also with increased mitochondrial
permeability and respiration (Si et al., 2013), strongly suggesting
extensive mitochondrial dysfunction and H2S deficiency in the
retina in DR. Vascular mitochondrial impairment induced by
diabetes has previously been shown to be inhibited/reversed
by sulfide administration albeit at high doses/concentrations
(e.g., 300 µmol/L) (Módis et al., 2013; Coletta et al., 2015),
suggesting that pharmacological sulfide could overcome impaired
retinal bioenergetics in DR. Although NaSH administration has
previously been shown to reduce retinal vascular abnormalities
associated with DR and “correct” mitochondrial dysfunction (Si
et al., 2013), this earlier study is intriguing for several reasons.
Firstly, the NaSH was given as a daily intraperitoneal injection
(over 14 weeks) at a dose equivalent to 280 mmol/kg. This was
an exceptionally high and surprisingly non-lethal dose (although
toxicity was not examined) given that 14 µmol/kg i.p. induces
systemic inflammation and vascular collapse (Li et al., 2005)
and the LD50 for NaSH is 52.6 µmol/kg for the same route
of administration (Strickland et al., 2003). Possible toxicological
constraints aside, the half-life of bolus sulfide in blood is less
than a minute as it is rapidly metabolized/removed (Wang, 2002,
2012), so the precise mechanisms by which a bolus of H2S
(from NaSH), administered intraperitoneally survives intact to
penetrate the blood–brain barrier and selectively increase sulfide
levels in the retina via this route remain elusive. Given that
plasma H2S levels have been measured at nanomolar to low
micromolar concentrations, our approach to prevent/reverse DR-
induced retinal vascular leakage using slow-release H2S donors
(Wei et al., 2014; John et al., 2017; Qiu et al., 2018) or H2S delivery
molecules that selectively target mitochondria (Le Trionnaire
et al., 2014; Szczesny et al., 2014; Ikeda et al., 2015; Ahmad et al.,
2016; Karwi et al., 2017) would overcome these concerns.
CONCLUSION
The data presented here together with previous in vivo data
(Whiteman et al., 2010a) suggest that, in health, H2S is
vasculoprotective and that microvascular dysfunction in diabetes,
including DR, is associated with reduced circulating and
retinal H2S levels. Thus, diabetes may be a condition of H2S
deficiency and H2S supplementation using slow-release and/or
mitochondrial-targeted H2S delivery molecules may represent a
novel, cost-effective alternative therapy for DR.
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